9.5.2003 Official Journal of the European Union L 11575 COMMISSION COMMISSION DECISION of 28 March 2003 on the allocation of quantities of controlled substances allowed for essential uses in the Commu- nity in 2003 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2003) 747) (Only the Danish, Dutch, English, Finnish, French, German, Italian, Portuguese, Spanish and Swedish texts are authentic) (Text with EEA relevance) (2003/316/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer ('), as last amended by Commission Decision 2003/160/EC (3), and in particular to Articles 3(1) and 7 thereof; Whereas: 1 The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetra- chloride, 1,1,1-trichloroethane, hydrobromofluorocar- bons and bromochloromethane. Each year the Commission has to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them. Decision IV[25 of the Parties to the Montreal Protocol on substances that deplete the ozone layer, hereinafter ‘the Montreal Protocol, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances. Decision X/19 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in L 244, 29.9.2000, p. 1. o) OJ L 65, 8.3.2003, p. 29. Annexes A and B of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the condi- tions set out in Annex II to the report of the Sixth Meeting of the Parties, Decision VII/11 and Decision XI/ 15 of the Parties to the Montreal Protocol. (5)  Substances required for essential uses that are not listed in Annexes A and B of the Montreal Protocol must be specifically approved by the Parties. This requirement applies to essential uses of hydrobromofluorocarbons and bromochloromethane that are listed in Annex C of the Montreal Protocol. (6)  Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluoro- carbon-free  Metered-Dose Inhalers (MDIs), Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Luxembourg, Norway, Portugal, the Netherlands and the United Kingdom have recently determined that chloro- fluorocarbons (CFCs) are no longer essential for the manufacture of specific short-acting beta agonist CFC- MDIs (). Article 4(4)(i)(b) of Regulation (EC) No 2037/ 2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the () www.unep.org/ozone/dec12-2-3.shtml